Ibodutant

Research use only, not for human use.

A potent and selective linear tachykinin NK2 receptor antagonist with pKb of 9.3; displays >1,000-fold selectivity over NK1 and NK3 (pKb<6).

A potent and selective linear tachykinin NK2 receptor antagonist with pKb of 9.3; displays >1,000-fold selectivity over NK1 and NK3 (pKb<6); induces a concentration-dependent rightward shift of the [βAla(8)]NKA(4-10) concentration-response curves without depressing the maximal contractile effect (3-100 nM); shows good in vivo activity after intravenous, intraduodenal, and oral administration in guinea pigs.Irritable Bowel Syndrome Phase 3 Clinical

MEN-15596;MEN 15596

GPCR/G Protein

Neurokinin Receptor

Neurokinin Receptor

Other Indications

Irritable Bowel Syndrome

522664-63-7

644.87

C37H48N4O4S

>98% (HPLC)

——

O=C(C1=CC2=CC=C(C)C=C2S1)NC3(C(N[C@H](CC4=CC=CC=C4)C(NCC5CCN(CC6CCOCC6)CC5)=O)=O)CCCC3

6-methyl-N-(1-(((R)-1-oxo-3-phenyl-1-(((1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)methyl)amino)propan-2-yl)carbamoyl)cyclopentyl)-2,3-dihydrobenzo[b]thiophene-2-carboxamide

(-20℃)

With Ice Pack

≥ 2 years